Cargando…
Update on the use of dutasteride in the management of benign prostatic hypertrophy
Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary tract infection, and acute uri...
Autores principales: | Miller, Joe, Tarter, Thomas H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684085/ https://www.ncbi.nlm.nih.gov/pubmed/18044081 |
Ejemplares similares
-
Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
por: Miller, J, et al.
Publicado: (2009) -
Preparation, Characterization and Stability Study of Dutasteride Loaded Nanoemulsion for Treatment of Benign Prostatic Hypertrophy
por: Ali, Mohammad Sajid, et al.
Publicado: (2014) -
Doxazosin in the treatment of benign prostatic hypertrophy: an update
por: Wilt, Timothy J, et al.
Publicado: (2006) -
Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride
por: Khedmati, Jamaleddin, et al.
Publicado: (2021) -
Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia
por: Thomson, Andrew
Publicado: (2005)